BioPharmaDispatch Conference.
Time to be together again
Sydney, Australia
16 May 2022
The Conference.
A day of powerful talks and a time to be together
16 May 2022
Four Seasons Hotel, George St, Sydney
About BPD.
What is the BPD conference?
The annual event of BioPharmaDispatch is a platform for the biopharmaceutical industry, its leaders, patients and key decision-makers to discuss issues impacting access to the latest healthcare technologies.
Early bird registration is available until early next year. Organisations can also request 'bespoke' registration packages that provide a combination of in-person and virtual attendance. This includes a 'license' for unlimited virtual attendance. Complimentary registration is available for patients and their representatives - contact@dailydispatch.com.au for more information.
+400
Participants
10
Sessions
25
Speakers
Speakers.
More speakers will be added once confirmed
Sponsors.
Conference Agenda.
8.30: Venue open.
9.00 - 9.30: The reality of Indigenous health
Dr Dawn Casey, deputy CEO, NACCHO
9.30 - 10.00: Reviews and reviews
Nicole Cooper, Convalis Consulting and patient advocate
Biljana Naumovic, Janssen
Katherine Burchfield, CEO, NPS MedicineWise
10.00 - 10.30: The Monday before the federal election
Jody Fassina, Insight Strategy
Felicity McNeill PSM, Better Access Australia
Associate Professor Ruth Colagiuri AM, Juvenile Arthritis Foundation Australia
10.30 - 11.00: Election implications and priorities
Liz de Somer, Medicines Australia
Richard Vines, Rare Cancers Australia
Lorraine Chiroiu, AusBiotech
11.00 - 11.30: Break
11.30 - 12.00 - Pharmaceutical Benefits Advisory Committee
Professor Andrew Wilson, PBAC
12.00 - 12.30 - The priorities for community pharmacy
Professor Trent Twomey, Pharmacy Guild of Australia
12.30 - 1.30: Lunch
1.30 - 2.00 - The Pharmac review, other issues and what now for NZ?
Dr Graeme Jarvis, Medicines New Zealand
2.00 - 2.30: ‘Past, present and future’
Kieran Schneemann, AstraZeneca
2.30 - 3.00 - ‘Track and trace’ and ‘price changes’
Richard Vincent, API and the National Pharmaceutical Services Association
3.00 - 3.30: Break
3.30 - 4.00: The health technology assessment review
Louise Graham, Pfizer
Paul Dale, Medical Technology Association of Australia
Simone Leyden, Neuroendocrine Cancer Australia
4.00 - 4.30: Wrap-up and insights
Chris Stemple, AbbVie
Adam Roach, BeiGene
Dr Kathryn Evans, BioMarin
Tanya Hall, hearts4heart
Professor John Zalcberg OAM
4.30 - 5.30 - Reception